Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims &…
30,569$
8,59%
Echtzeit-Aktienkurs Hims & Hers Health Inc.
Bid:
Ask:
Nachrichten zur Hims & Hers Health Inc. Aktie
Eli Lillys Oral Drug Clears CV Test, Hims Surges 14%
Eli Lillys oral obesity drug Foundayo passed cardiovascular safety testing while Hims & Hers surged 14% after the FDA scheduled…
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies
On April 16, 2026, investors monitored an FDA peptide review that could be a boost to Hims & Hers Health.…
HIMS Stock Rises 7% on Potential FDA Regulatory Changes
On April 16, 2026, Hims & Hers Health Inc (HIMS) saw its stock price increase by approximately 7% following statements…
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions
Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides,…
RFK Jr. Just Gave Hims & Hers Stock a Jolt. Should You Chase the Rally Here?
Hims & Hers stock rallies as RFK Jr. says FDA may remove restrictions on certain peptides. But HIMS shares remain…
Hims & Hers shares surge 8% on promising FDA peptide review
Hims & Hers stock jumped 8% after the FDA announced a formal review of wellness peptides for compounding, with Bank…
RFK Jr.s peptide policy could boost Hims & Hers as its GLP-1 business evolves
Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping…
Hims & Hers: Der Befreiungsschlag steht bevor
Lange Zeit wurde die Aktie von Hims & Hers an der Börse fast ausschließlich als spekulatives Vehikel für den Hype…
Hims & Hers shares jump as FDA begins review of restricted peptide compounds
Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug…
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.…
Push to ease peptide restrictions positive for Hims & Hers, says Leerink
Leerink analyst Michael Cherny views Health and Human Services Secretary Robert Kennedy announcement that the FDA is seeking to remove…
Hims & Hers Health (HIMS) Jumps 6.6% to $26.03
Hims & Hers Health shares jumped 6.6% Thursday to $26.03 after B of A Securities boosted its price target by…
Hims & Hers stock extends gains as RFK Jr. signals FDA will consider looser restrictions on peptides
Hims & Hers stock jumped as RFK Jr. signaled that the FDA may ease restrictions on certain peptides.…
BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?
Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on…
BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?
Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on…
BofA Raises Hims & Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?
Hims & Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on…
Market movers: Hims & Hers, Abbott Laboratories, QVC…
…
HIMS Plunges 51.2% in 6 Months: Should You Still Hold the Stock or Sell?
Hims & Hers rolls out Benefits and taps Novo Nordisk for GLP therapies in weight-loss care as revenue grows, but…